Clinical Research · global
A Cell Therapy Signal in Refractory Rheumatoid Arthritis: Three of Six Trial Participants Remain in Drug-Free Remission
A single CAR T-cell infusion allowed some patients who had not improved despite multiple treatments to remain off arthritis medications during follow-up. This early trial also identified signs of changes in B-cell composition, but larger comparative studies are needed to determine how long the benefits last and what safety trade-offs they entail.
When one medication after another fails to control joint inflammation, patients face not only pain but an increasingly restricted life. A German research team tried to address this predicament with modified immune cells: all six patients with severe, refractory rheumatoid arthritis experienced improvements in disease activity after receiving CAR T-cell therapy, and three remained in remission without arthritis medications at the end of observation.
This was the nonrandomized phase 1 study of the COMPARE trial, initiated by Charité—Universitätsmedizin Berlin, with participation from institutions including the German Rheumatism Research Centre (DRFZ). The results were published in *Nature Medicine* on August 27, 2026. The participants were three women and three men, aged 31 to 69, all positive for anti-citrullinated protein antibodies (ACPA). They had previously received multiple treatments, including up to eight targeted therapies or biologics, without sufficient improvement.
The treatment used in the study, mivocabtagene autoleucel (miv-cel), is a cellular product made by modifying patients’ own T cells to recognize CD19. CD19 is present on the surface of many B cells and is not a marker exclusive to disease-causing cells; the treatment aims to eliminate these cells to disrupt the processes that sustain the autoimmune response. Patients first stopped disease-modifying antirheumatic drugs, then received lymphocyte-depleting pretreatment, and finally received their modified T cells back in a single infusion. That single infusion therefore still involves a full treatment process.
During 36 to 52 weeks of follow-up, disease activity decreased in all six participants. At the latest assessment, three met the DAS28-CRP remission criteria, calculated using 28 joints and C-reactive protein, as well as the American College of Rheumatology’s ACR70 response criteria. Both Charité and DRFZ reported that three participants remained in remission without arthritis medications until the end of observation; however, Charité also stated that another participant relapsed after initially achieving drug-free remission. These results suggest that some patients may experience sustained improvement, but they do not establish that the disease has been cured.
Beyond the clinical changes, the team also investigated how the immune system rebuilt itself. According to Charité, younger cells predominated when B cells returned, and previously detected autoreactive B cells temporarily became undetectable in almost all participants; disease-associated autoantibodies also declined markedly. Protective antibodies against infections such as chickenpox and tetanus were retained. These observations support research into “resetting abnormal immune memory,” but they cannot prove that all disease-causing cells have disappeared and are insufficient to determine whether long-term immune protection remains intact.
The safety results also require careful interpretation. All six participants developed grade 1 or grade 2 cytokine release syndrome, and the trial observed no immune effector cell-associated neurotoxicity syndrome (ICANS) or serious adverse events. However, one participant developed a grade 3 elevation in transaminases, classified as a dose-limiting toxicity, which subsequently resolved without lasting effects. The phase 1 study primarily assessed safety during the first four weeks after treatment. With six participants and follow-up ranging from less than a year to approximately a year, it remains insufficient to rule out rare or later-emerging risks.
Next, the research team plans to enroll another ten patients in the second part of the study and compare the treatment with a drug already approved for rheumatoid arthritis that also targets B cells, to clarify whether CAR T cells can deliver stronger, more lasting effects. This investigator-initiated trial received funding and miv-cel from Kyverna Therapeutics; the paper states that the funder had no role in study design, data collection, analysis, interpretation, or report writing. For patients who have not responded to multiple treatments, this offers a new clinical signal; to become a treatment option that can be adopted, its long-term benefits must still be shown to outweigh the risks of the full treatment course.